Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | ACACA | Q13085 | 3/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960795 | 0.88 | DRD2 (0.45) | DRD2MTNR1AMTNR1BNAMPTACACB | |
| SCHEMBL29960335 | 0.81 | ACACB (0.44) | DRD2NAMPTACACBACACACKS1B | |
| SCHEMBL27214605 | 0.75 | HTR1A (0.40) | DRD2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL29923119 | 0.75 | HTR1A (0.40) | DRD2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL29923116 | 0.75 | HTR1A (0.40) | DRD2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL29923181 | 0.75 | HTR1A (0.40) | DRD2MTNR1AMTNR1BACACBACACA | |
| SCHEMBL29923228 | 0.75 | HTR1A (0.40) | DRD2MTNR1AMTNR1BACACBACACA | |
| Hydrochloric Acid SCHEMBL29960397 | 0.74 | HTR2A (0.45) | — | |
| SCHEMBL29960757 | 0.72 | ACACB (0.39) | DRD2ACACBACACACKS1BSKP1 | |
| SCHEMBL29960742 | 0.72 | FFAR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |